Publications by authors named "Peter Patriarca"

Claim this Profile
I
Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research.
Constantina Boikos, Mahrukh Imran, Simon De Lusignan, Justin R Ortiz, Peter A Patriarca

Vaccines (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pivotal Vaccine Efficacy Trials-Study Design Considerations from a Vaccine Trial Design Working Group.
Patricia B Pavlinac, Elizabeth T Rogawski McQuade, James A Platts-Mills, Karen L Kotloff, Carolyn Deal, Peter Patriarca

Vaccines (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience.
Uwe Nicolay, Esther Heijnen, Pantaleo Nacci, Peter A Patriarca, Brett Leav

Int J Infect Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market.
Peter A Patriarca, R Michael Van Auken, Scott A Kebschull

Ther Innov Regul Sci· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial.
Lisa M Dunkle, Ruvim Izikson, Peter A Patriarca, Karen L Goldenthal, Manon Cox

Pediatrics· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
Lisa M Dunkle, Ruvim Izikson, Peter A Patriarca, Karen L Goldenthal, Derek Muse

J Infect Dis· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older.
Lisa M Dunkle, Ruvim Izikson, Peter Patriarca, Karen L Goldenthal, Derek Muse

N Engl J Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.
John J Treanor, Laurence Chu, Brandon Essink, Derek Muse, Hana M El Sahly, Peter Patriarca

Vaccine· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.
Ruvim Izikson, David J Leffell, S Allan Bock, Peter A Patriarca, Penny Post

Vaccine· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.
Jeannette M Watson, James N Francis, Sofie Mesens, Gabriel A Faiman, Jill Makin, Peter Patriarca

Virol J· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
John J Treanor, Brandon Essink, Steven Hull, Steven Reed, Ruvim Izikson, Peter Patriarca

Vaccine· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert review on poliovirus immunity and transmission.
Radboud J Duintjer Tebbens, Mark A Pallansch, Konstantin M Chumakov, Neal A Halsey, Tapani Hovi, Peter A Patriarca

Risk Anal· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.
Radboud J Duintjer Tebbens, Mark A Pallansch, Konstantin M Chumakov, Neal A Halsey, Tapani Hovi, Peter A Patriarca

Risk Anal· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research and development and the polio eradication initiative: too much, too soon...too little, too late?
Peter A Patriarca

Clin Infect Dis· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.
John J Treanor, Hana El Sahly, James King, Irene Graham, Ruvim Izikson, Peter Patriarca

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
James C King, Manon M Cox, Keith Reisinger, James Hedrick, Irene Graham, Peter Patriarca

Vaccine· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FluBlok, a recombinant hemagglutinin influenza vaccine.
Manon M J Cox, Peter A Patriarca, John Treanor

Influenza Other Respir Viruses· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparing for pandemic influenza: the need for enhanced surveillance.
Kathleen F Gensheimer, Keiji Fukuda, Lynette Brammer, Nancy Cox, Peter A Patriarca

Vaccine· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis